Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective

被引：2
|
作者：
Gan, Qiming [1 ]
Wu, Yanjuan [1 ]
Su, Xiaofen [1 ]
Wang, Jingcun [1 ]
Zhang, Haojie [1 ]
Zhang, Nuofu [1 ]
Wu, Kang [1 ]
机构：
[1] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Ctr Resp Dis, Natl Clin Res Ctr Resp Dis,Affiliated Hosp 1,Stat, Guangzhou, Peoples R China
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷 / 02期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1164/rccm.202307-1143LE
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：223 / 224
页数：3
相关论文
共 50 条
  • [21] A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
    Singh, Dave
    Martinez, Fernando J.
    Watz, Henrik
    Bengtsson, Thomas
    Maurer, Brian T.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [22] Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial
    Ferguson, G. T.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [23] Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2
    Siler, T. M.
    Rickard, K.
    Bengtsson, T.
    Rheault, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [24] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Improved Dyspnea in Subjects With Symptomatic, Moderate-to-Severe COPD Over 24 Weeks
    Mahler, D. A.
    Bhatt, S. P.
    Singh, D.
    Rheault, T.
    Reyner, D.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [25] Late Breaking Abstract - A Dose-Ranging Study of the Inhaled Dual PDE3/4 Inhibitor TQC3721 in COPD Patients
    Luo, Zhu
    Yang, Ling
    Yang, Anqi
    Li, Weiguo
    Yu, Ding
    Li, Weimin
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [26] Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors
    Halpin, David M. G.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2006, 67 (07) : 370 - 374
  • [27] Pharmacotherapy of chronic obstructive pulmonary disease: Therapeutic considerations with a focus on inhaled corticosteroids
    Irusen, Elvis M.
    Malange, Thandeka D.
    SOUTH AFRICAN FAMILY PRACTICE, 2020, 62 (01) : 1 - 6
  • [28] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Reduced Moderate/Severe Exacerbation Rate and Risk in Subjects With COPD Regardless of Baseline Blood Eosinophils
    Sciurba, F. C.
    Christenson, S.
    Rheault, T.
    Reyner, D.
    Bengtsson, T.
    Rickard, K.
    Barjaktarevic, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [29] Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective
    Babu, K. Suresh
    Kastelik, Jack A.
    Morjaria, Jaymin B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (02) : 282 - 300
  • [30] Treatment With Ensifentrine, a Dual PDE3 and PDE4 Inhibitor, Significantly Reduced Exacerbation Rate and Risk in Subjects With COPD: Sub-group Results From the Phase 3 Trial, Enhance-2
    Anzueto, A.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
12345